Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability

Journal of Pharmaceutical Sciences

Volumn 102, Issue 4, 2013, Pages 1343-1354

  Sane, Ramola ^a   Mittapalli, Rajendar K ^a   Elmquist, William F ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

ABC Transporters; Bioavailability; Elacridar; GF120918; Microemulsion; Preclinical pharmacokinetics; Target drug delivery

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CREMOPHOR; DASATINIB; DIETHYLENE GLYCOL MONOETHYL ETHER; ELACRIDAR; ERLOTINIB; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG PENETRATION; DRUG SOLUBILITY; MAXIMUM PLASMA CONCENTRATION; MDCK CELL; MICROEMULSION; MOUSE; NONHUMAN; PARTITION COEFFICIENT; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84874669561     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23450     Document Type: Article

References (38)

1. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. 1993. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53(19):4595-4602.
2. Witherspoon SM, Emerson DL, Kerr BM, Lloyd TL, Dalton WS, Wissel PS. 1996. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin Cancer Res 2(1):7-12.
3. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH. 1999. The mouse Bcrp1/Mxr/Abcp gene: Amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 59(17):4237-4241.
4. Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, Schellens JH. 2002. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 20(13):2943-2950.
5. Kuppens IE, Witteveen EO, Jewell RC, Radema SA, Paul EM, Mangum SG, Beijnen JH, Voest EE, Schellens JH. 2007. A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin Cancer Res 13(11):3276-3285.
6. Bardelmeijer HA, Ouwehand M, Beijnen JH, Schellens JH, van Tellingen O. 2004. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Invest New Drugs 22(3):219-229.
7. Edwards JE, Brouwer KR, McNamara PJ. 2002. GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats. Antimicrob Agents Chemother 46(7):2284-2286.
8. Letrent SP, Pollack GM, Brouwer KR, Brouwer KL. 1998. Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat. Pharm Res 15(4):599-605.
9. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, Schellens JH. 2005. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65(7):2577-2582.
10. Chen Y, Agarwal S, Shaik NM, Chen C, Yang Z, Elmquist WF. 2009. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J Pharmacol Exp Ther 330(3):956-963.
11. Agarwal S, Sane R, Gallardo JL, Ohlfest JR, Elmquist WF. 2010. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther 334(1):147-155.
12. Sane R, Agarwal S, Elmquist WF. 2012. Brain distribution and bioavailability of elacridar after different routes of administration in the mouse. Drug Metab Dispos 40(8):1612-1619.
13. Ward KW, Azzarano LM. 2004. Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9, 10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1, 2, 3, 4-tetrahydro-6, 7-dimethoxy-2-i soquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey. J Pharmacol Exp Ther 310(2):703-709.
14. Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, Schinkel AH. 2012. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer 130(1):223-233.
15. Talegaonkar S, Azeem A, Ahmad FJ, Khar RK, Pathan SA, Khan ZI. 2008. Microemulsions: A novel approach to enhanced drug delivery. Recent Pat Drug Deliv Formul 2(3):238-257.
16. Narang AS, Delmarre D, Gao D. 2007. Stable drug encapsulation in micelles and microemulsions. Int J Pharm 345(1-2):9-25.
17. Bagwe RP, Kanicky JR, Palla BJ, Patanjali PK, Shah DO. 2001. Improved drug delivery using microemulsions: Rationale, recent progress, and new horizons. Crit Rev Ther Drug Carrier Syst 18(1):77-140.
18. Lawrence MJ, Rees GD. 2000. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 45(1):89-121.
19. Regev R, Katzir H, Yeheskely-Hayon D, Eytan GD. 2007. Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane. FEBS J 274(23):6204-6214.
20. Gao Zhong-Gao H-GC, Hee-Jong Shin, Kyung-Mi Park, Soo-Jeong Lim, Ki-Jun Hwang, Chong-Kook Kim. 1998. Physicochemical characterization and evaluation of a microemulsion system for oral delivery of cyclosporin A. Int J Pharm 161(1):75-86.
21. Kemper EM, van Zandbergen AE, Cleypool C, Mos HA, Boogerd W, Beijnen JH, van Tellingen O. 2003. Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. Clin Cancer Res 9(7):2849-2855.
22. Shaik N, Giri N, Elmquist WF. 2009. Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: Cell accumulation and equilibrium dialysis studies. J Pharm Sci 98(11):4170-4190.
23. de Vries NA, Buckle T, Zhao J, Beijnen JH, Schellens JH, van Tellingen O. 2012. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs 30(2):443-449.
24. Elmeliegy MA, Carcaboso AM, Tagen M, Bai F, Stewart CF. 2011. Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res 17(1):89-99.
25. Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH. 2008. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther 7(8):2280-2287.
26. Araya H, Nagao S, Tomita M, Hayashi M. 2005. The novel formulation design of self-emulsifying drug delivery systems (SEDDS) type O/W microemulsion I: Enhancing effects on oral bioavailability of poorly water soluble compounds in rats and beagle dogs. Drug Metab Pharmacokinet 20(4):244-256.
27. Scott Swenson E, Curatolo WJ. 1992. (C) Means to enhance penetration: (2) Intestinal permeability enhancement for proteins, peptides and other polar drugs: Mechanisms and potential toxicity. Adv Drug Deliv Rev 8(1):39-92.
28. Morey TE, Modell JH, Shekhawat D, Grand T, Shah DO, Gravenstein N, McGorray SP, Dennis DM. 2006. Preparation and anesthetic properties of propofol microemulsions in rats. Anesthesiology 104(6):1184-1190.
29. Wang Y, Wu KC, Zhao BX, Zhao X, Wang X, Chen S, Nie SF, Pan WS, Zhang X, Zhang Q. 2011. A novel paclitaxel microemulsion containing a reduced amount of Cremophor EL: Pharmacokinetics, biodistribution, and in vivo antitumor efficacy and safety. J Biomed Biotechnol 2011:854872.
30. Agarwal S, Sane R, Oberoi R, Ohlfest JR, Elmquist WF. 2011. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med 13:e17.
31. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J. 1999. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications. Cancer Res 59(7):1454-1457.
32. Cuine JF, Charman WN, Pouton CW, Edwards GA, Porter CJ. 2007. Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs. Pharm Res 24(4):748-757.
33. Ovando-Medina VM, Mendizábal E, Peralta RD. 2005. Kinetics modeling of microemulsion copolymerization. Polym Bull 54(1):129-140.
34. Agarwal S, Manchanda P, Vogelbaum MA, Ohlfest JR, Elmquist WF. 2012. Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: Findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos 41(1):33-39.
35. Kesavabhotla K, Schlaff CD, Shin B, Mubita L, Kaplan R, Tsiouris AJ, Pannullo SC, Christos P, Lavi E, Scheff R, Boockvar JA. 2012. Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma. J Exp Ther Oncol 10(1):71-81.
36. Prados MD, Lamborn KR, Chang S, Burton E, Butowski N, Malec M, Kapadia A, Rabbitt J, Page MS, Fedoroff A, Xie D, Kelley SK. 2006. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol 8(1):67-78.
37. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD. 2010. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol 12(1):95-103.
38. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Friedman AH, Herndon JE, 2nd, Marcello J, Norfleet JA, McLendon RE, Sampson JH, Friedman HS. 2010. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 96(2):219-230.